← All Compounds
Mechanism Synthetic cyclic heptapeptide, non-selective melanocortin receptor agonist with preferential activity at MC4R. Activates central nervous system pathways involved in sexual arousal. Does not act on PDE5 or the vasculature. Half-Life Approximately 2.5 hours Route subcutaneous Frequency As needed, max 1 dose per 24 h
Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.
PT-141
FDA Approved
Neuropeptide · Palatin Technologies (Vyleesi)
Melanocortin-4 receptor agonist approved by the FDA in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Acts centrally on nervous system pathways rather than on the vascular system.
About
Clinical Dosing
1.75 mgas needed, max 1 dose per 24 h
Approved product (Vyleesi) available by prescription. Not on FDA Category 2 list.
FDA-approved dose: 1.75 mg SC as needed, at least 45 minutes before anticipated sexual activity. Maximum one dose per 24 hours, not more than 8 doses per month (Vyleesi label).
Titration Protocols
Vyleesi Label (HSDD, premenopausal women)
Source: Vyleesi (bremelanotide) Prescribing Information, FDA 2019
| Dose | Duration | Draw (1 mg vial in 2mL) | Notes |
|---|---|---|---|
| 1.75 mg | Maintenance | 3.50 mL (350 units) | SC as needed, ≥45 min before activity. Max 1 dose / 24 h, max 8 doses / month. |
Available Vial Sizes
1 mg
1 mg vial
2 mg
2 mg vial
5 mg
5 mg vial